Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 in relapsed/refractory extranodal NK/T-cell lymphoma (nasal type)
CTR20171454Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Hengrui Therapeutics. Started Dec 2017; status: active.
02
Drugs
camrelizumab
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on CTR20171454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171454.